Want to see HK:2511 full AI Analyst Report?
Hightide Therapeutics Inc (2511) AI Stock Analysis
Hightide Therapeutics Inc
(HKEX:2511)
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and persistent cash burn despite balance-sheet improvement). Technicals are a meaningful offset, with price strength above major moving averages and positive momentum indicators. Valuation provides limited support due to a negative P/E and no dividend yield.
Hightide Therapeutics Inc (2511) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.58B
- Dividend Yield
- ―
- Average Volume (3M)
- 782.20K
- Price to Earnings (P/E)
- -4.9
- Beta (1Y)
- 1.10
- Revenue Growth
- ―
- EPS Growth
- 14.40%
- Country
- Hong Kong
- Employees
- 51
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Hightide Therapeutics Inc Business Overview & Revenue Model
Company Description
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabo...
Hightide Therapeutics Inc Financial Statement Overview
Summary
Overall financials remain high-risk: zero reported revenue across periods, persistent net losses, and consistently negative operating/free cash flow. A notable positive is the balance-sheet repair since 2022 (equity back to positive and leverage more manageable), but ongoing cash burn and losses still dominate the financial profile.
Income Statement
18Very NegativeBalance Sheet
45NeutralCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -172.88M | -217.31M | -438.86M | -446.41M | -224.81M | -130.49M |
| Net Income | -270.91M | -244.97M | -381.79M | -939.31M | -190.24M | -221.15M |
Balance Sheet | ||||||
| Total Assets | 378.38M | 551.58M | 559.93M | 795.04M | 855.82M | 777.23M |
| Cash, Cash Equivalents and Short-Term Investments | 326.36M | 502.94M | 490.52M | 735.70M | 828.33M | 763.91M |
| Total Debt | 154.73M | 126.92M | 77.91M | 16.43M | 1.27B | 1.01B |
| Total Liabilities | 203.11M | 186.75M | 135.76M | 92.26M | 1.33B | 1.05B |
| Stockholders Equity | 166.98M | 307.14M | 424.17M | 702.77M | -470.53M | -271.77M |
Cash Flow | ||||||
| Free Cash Flow | -154.34M | -166.98M | -299.46M | -368.56M | -172.90M | -90.12M |
| Operating Cash Flow | -154.05M | -166.91M | -294.81M | -367.67M | -172.71M | -88.40M |
| Investing Cash Flow | 95.53M | -102.90M | -89.72M | 321.64M | -415.66M | 1.59M |
| Financing Cash Flow | 146.35M | 199.72M | 54.79M | 399.46M | 46.03M | 493.98M |
Hightide Therapeutics Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2511, the sentiment is Negative. The current price of 3.10 is below the 20-day moving average (MA) of 3.24, below the 50-day MA of 3.28, and below the 200-day MA of 3.10, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 42.57 is Neutral, neither overbought nor oversold. The STOCH value of 53.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2511.
Hightide Therapeutics Inc Peers Comparison
Overall Rating
HK:218157Neutral
HK:248753.5Neutral- HK:251152Neutral
HK:122849Neutral
HK:368143Neutral
HK:662837Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2181 | 57Neutral | HKD 1.79B | 17.76 | 48.25% | ― | 88.38% | ― |
| HK:2487 | 54Neutral | HKD 259.84M | -0.74 | -35.24% | ― | 35.47% | 46.42% |
| HK:2511 | 52Neutral | HKD 1.88B | -4.86 | -114.28% | ― | ― | 14.40% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1228 | 49Neutral | HKD 1.06B | -9.50 | 30.32% | ― | -8.00% | 51.26% |
| HK:3681 | 43Neutral | HKD 1.47B | -6.84 | -41.81% | ― | ― | -4.24% |
| HK:6628 | 37Underperform | HKD 327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2511 | Hightide Therapeutics Inc | 3.10 | -0.67 | -17.77% | |
| HK:1228 | CANbridge Pharmaceuticals Inc. | 1.77 | -0.21 | -10.61% | |
| HK:2181 | Mabpharm Limited | 0.43 | -0.09 | -16.35% | |
| HK:3681 | SinoMab Bioscience Ltd. | 1.07 | -0.70 | -39.55% | |
| HK:6628 | Transcenta Holding Limited | 0.73 | -2.31 | -75.90% | |
| HK:2487 | Cutia Therapeutics | 0.69 | -6.80 | -90.79% |
Hightide Therapeutics Inc Corporate Events
HighTide Therapeutics Ends Concert Party Agreement, Founder Remains Largest Shareholder
HighTide Therapeutics Inc. has announced the termination of a concert party agreement among founder-related and investor entities, effective October 30, 2026. The agreement had previously aligned the voting behavior of Founder BVI, Greaty Investment,...
HighTide Therapeutics Grants Performance-Linked Share Options and Awards
HighTide Therapeutics has granted 2,040,450 share options and 306,749 share awards under its 2025 Share Incentive Plan, representing about 0.30% and 0.05% of its outstanding share capital, respectively. The grants include a significant allocation to...
HighTide Therapeutics Highlights HTD1801 as Foundational CKM Therapy in Interim Results
HighTide Therapeutics has reported its unaudited interim results for the six months ended June 30, 2026, alongside comparative figures for the prior year period, underscoring ongoing investment in its cardiovascular-kidney-metabolic disease pipeline....
HighTide Therapeutics Sets Board Meeting to Approve Interim Results
HighTide Therapeutics Inc. has scheduled a board meeting for August 31, 2026, to review and approve the interim results for the six months ended June 30, 2026. The board will also address other corporate matters, signaling the forthcoming release of...
HighTide Therapeutics Raises HK$225 Million Through Share Placing to Fund HTD1801 Expansion
HighTide Therapeutics has completed a placing of 98,710,000 new shares under its general mandate, raising approximately HK$225.1 million in gross proceeds at HK$2.28 per share through at least six independent investors. The transaction, which closed...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 10, 2026